ERBB2 and head and neck squamous cell carcinoma: According to a phase III trial, there are no survival benefits associated with lapatinib, a small-molecule inhibitor of EGFR and of the human epidermal growth factor receptor 2 (HER2, ErbB2), neither when paired with chemoradiation nor when used as a maintenance monotherapy in patients with high-risk surgically-treated SCCHN [34].